Mycovia has reached agreement on pivotal study designs with the US Food and Drug Administration, European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency.
The additional randomised, double-blind ultraVIOLET Phase 3 trial will be conducted in the United States with approximately 45 sites and 180 randomized patients.
The company expects to complete all three Phase 3 trials of the RVVC program in the second half of 2020 in anticipation of regulatory submissions.
VT-1161 is an orally available inhibitor of fungal CYP51 being developed by Mycovia for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. VT-1161 is designed to have greater selectivity, fewer side effects and improved potency.
Recurrent vulvovaginal candidiasis is a debilitating, chronic infectious condition that affects ms of women. Primary symptoms include vaginal itching, burning, irritation and inflammation.
Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain.
RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine, yet despite the high prevalence, there are currently no agents in the United States approved to treat the condition.
Mycovia is in developing targeted therapies in women's health and dermatology. The company was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management.
NovaQuest Capital Management is an investor in life sciences and healthcare through its BioPharma and Private Equity strategies.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer